Velosity Capital
VC Fund
Velosity Capital is a VC fund focused on Biotechnology and Health Care. Velosity Capital operates as an investment firm.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries Velosity Capital invests in
Stages Velosity Capital invests in
Countries Velosity Capital invests in
Investment Focus
Industry
- Biotechnology 5 (50%)
- Health Care 3 (30%)
- Medical 2 (20%)
- Biopharma 2 (20%)
- Pharmaceutical 2 (20%)
Stage
- Series B 3 (30%)
- Series A 2 (20%)
- Series C 2 (20%)
- Series D 1 (10%)
- Venture - Series Unknown 1 (10%)
Country
- United States 6 (60%)
- Australia 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M / Series D / Jul 15, 2026 | |
Diagonal Therapeutics
|
Diagonal Therapeutics is a biotechnology startup that is pioneering a novel technique to finding and producing agonist antibodies. Diagonal Therapeutics platform combines novel computational and experimental methodologies to solve the traditional obstacles associated with agonist antibody drug development. | $125M / Series B / Jan 08, 2026 | |
Endeavor BioMedicines
|
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis. The company was founded in 2018 and is based in Solana Beach, California, United States. | $132.5M / Series C / Apr 24, 2024 | |
|
Diagonal Therapeutics
|
Diagonal Therapeutics is a biotechnology startup that is pioneering a novel technique to finding and producing agonist antibodies. Diagonal Therapeutics platform combines novel computational and experimental methodologies to solve the traditional obstacles associated with agonist antibody drug development. | $128M / Series A / Apr 03, 2024 | |
Sudo Biosciences
|
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $30M / Series B / Feb 13, 2024 | |
|
Sudo Biosciences
|
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $116M / Series B / Dec 20, 2023 | |
|
Sudo Biosciences
|
Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $37M / Series A / Sep 28, 2022 | |
Koneksa Health
|
Koneksa Health is a healthcare data analytics company that helps researchers incorporate emerging technologies (bio-sensors, activity trackers, mobile-based questionnaires, etc.) into their clinical studies. Their Koneksa Compare software dashboard enables the collection, visualization, and analysis of these patient-generated data sets.Koneksacurrently supports academic and life sciences researchers, expands the universe of data that can be analyzed while also removing subjective characteristics from clinical endpoints. It was founded in 2015 and is based in New York, United States. | $45M / Series C / Feb 07, 2022 | |
Wugen
|
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cellmalignancies. | $172M / Series B / Jul 15, 2021 | |
Aura Biosciences
|
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives ofpeople with a wide range of cancers that are poorly managed today.The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts. | $80M / Venture - Series Unknown / Mar 22, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Velosity Capital invest in?
Velosity Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Velosity Capital last invest?
The most recent investment recorded for Velosity Capital closed in Jul 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
